RELAPSE
Clinical trials for RELAPSE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE trials appear
Sign up with your email to follow new studies for RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy called CAR-T cells that target a protein called B7-H3 on triple-negative breast cancer cells. The cells also have a safety switch to stop them if needed. Up to 42 adults whose cancer has returned or not responded…
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Talking it out: new study tests if coaching after detox keeps booze at bay
Disease control Recruiting nowThis study looks at whether having regular motivational conversations after leaving the hospital for alcohol withdrawal can help people stay sober longer. About 104 adults who want to quit drinking completely will be split into two groups: one gets standard care, the other also g…
Matched conditions: RELAPSE
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on tough pancreatic cancer
Disease control Recruiting nowThis early-phase study tests a new gene therapy for people with pancreatic cancer that has returned after standard treatment. The therapy uses a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side eff…
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Early-Relapse colorectal cancer: immune booster added to chemo
Disease control Recruiting nowThis study is for people with colorectal cancer that came back within a year after finishing initial chemotherapy. It tests whether adding an immunotherapy drug called serplulimab to standard second-line chemo and targeted therapy can help control the cancer longer. About 40 part…
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis phase 2 study is testing whether combining two drugs—epcoritamab and loncastuximab tesirine—can safely shrink or eliminate lymphoma in people whose large B-cell lymphoma has come back or not responded to treatment. About 26 adults will receive the drugs over several cycles. …
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered immune cells take on recurrent head and neck cancer
Disease control Recruiting nowThis study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to fin…
Matched conditions: RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New CAR-T therapy aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis study tests a new type of immunotherapy called CAR-T cells, which are specially engineered to recognize and attack CD30, a protein found on Hodgkin lymphoma cells. The trial enrolls up to 31 adults whose cancer has returned or not responded to standard treatments. Participan…
Matched conditions: RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
AI model aims to predict ABPA relapse risk
Knowledge-focused Recruiting nowThis study is developing a machine learning model to predict the risk of relapse within one year for people with allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a fungus. Researchers will collect data from 300 patients across mul…
Matched conditions: RELAPSE
Sponsor: Qianfoshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Face shape may predict how teeth shift after braces
Knowledge-focused Recruiting nowThis study looks at how different face shapes (horizontal vs. vertical growers) affect tooth movement after braces are removed, during the retention phase when retainers are worn. Researchers will track 44 people over 12 months using 3D scans to see if teeth shift differently bas…
Matched conditions: RELAPSE
Phase: NA • Sponsor: Postgraduate Institute of Dental Sciences Rohtak • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC